Buys | $0 | 0 | 0 |
Sells | $11,617 | 3 | 100 |
Firmani Lori | Interim CFO | 0 | $0 | 1 | $1,469 | $-1,469 |
Winslow Garrett | General Counsel | 0 | $0 | 1 | $2,638 | $-2,638 |
Schambye Hans T. | Chief Executive Officer | 0 | $0 | 1 | $7,510 | $-7,510 |
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 …
Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $11,617 worth of Galecto, Inc. stock.
On average, over the past 5 years, insiders at Galecto, Inc. have bought $14.71M and sold $1.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.
2025-01-03 | Sale | Schambye Hans T. | Chief Executive Officer | 1,341 0.1037% | $5.60 | $7,510 | -17.72% | |
2025-01-03 | Sale | Winslow Garrett | General Counsel | 471 0.0364% | $5.60 | $2,638 | -17.72% | |
2025-01-03 | Sale | Firmani Lori | Interim CFO | 261 0.0203% | $5.63 | $1,469 | -17.72% | |
2023-08-15 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 822,680 3.5684% | $0.75 | $617,010 | -7.48% | |
2023-07-31 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 209,400 0.8023% | $3.00 | $628,200 | -79.55% | |
2023-07-25 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,200 0.1462% | $2.92 | $114,464 | -79.34% | |
2023-07-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 194,700 0.7339% | $2.40 | $467,280 | -74.19% | |
2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 12,429 0.0461% | $1.97 | $24,485 | -66.21% | |
2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,089 0.0485% | $1.97 | $25,785 | -66.21% | |
2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,355 0.1501% | $1.86 | $73,200 | -63.13% | |
2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 41,446 0.158% | $1.86 | $77,090 | -63.13% | |
2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,243 0.0519% | $1.82 | $24,102 | -61.26% | |
2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0546% | $1.82 | $25,382 | -61.26% | |
2023-04-12 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 2,363 0.0093% | $1.81 | $4,277 | -60.83% | |
2023-04-11 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0543% | $1.82 | $25,382 | -61.41% | |
2023-04-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 51,228 0.1984% | $1.79 | $91,698 | -60.81% | |
2023-04-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 9,665 0.0396% | $2.00 | $19,330 | -62.87% | |
2023-04-05 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 92,965 0.3672% | $2.18 | $202,664 | -67.11% | |
2022-03-22 | Schambye Hans T. | Chief Executive Officer | 5,000 0.0194% | $2.15 | $10,750 | -12.79% | ||
2022-03-22 | Lindmark Bertil | Chief Medical Officer | 14,604 0.057% | $2.16 | $31,545 | -12.79% |
Schambye Hans T. | Chief Executive Officer | 3397 0.2579% | $13,757.85 | 3 | 1 | <0.0001% |
Winslow Garrett | General Counsel | 1009 0.0766% | $4,086.45 | 2 | 1 | <0.0001% |
Khuong Chau Quang | 2579657 195.8752% | $10.45M | 1 | 0 | ||
Novo Holdings A/S | 10 percent owner | 2497791 189.6591% | $10.12M | 1 | 0 | |
Christgau Stephan | director | 546136 41.4685% | $2.21M | 1 | 0 |
$18,881,323 | 88 | -48.96% | $4.47M | |
$296,936 | 37 | -18.12% | $4M | |
$523,320 | 24 | 94.37% | $7.01M | |
$31,129 | 22 | -11.96% | $6.19M | |
$51,865 | 17 | -38.70% | $6.16M |
Increased Positions | 5 | +38.46% | 20,188 | +15.69% |
Decreased Positions | 5 | -38.46% | 6,782 | -5.27% |
New Positions | 3 | New | 12,819 | New |
Sold Out Positions | 3 | Sold Out | 384 | Sold Out |
Total Postitions | 13 | company.total | 142,062 | +10.42% |
Novo Holdings A/S | $438.00 | 9.99% | 99,913 | 0 | 0% | 2024-12-31 |
Renaissance Technologies Llc | $66.00 | 1.5% | 15,044 | -6,338 | -29.64% | 2024-12-31 |
Squarepoint Ops Llc | $56.00 | 1.27% | 12,701 | +12,701 | New | 2024-12-31 |
Ubs Group Ag | $55.00 | 1.25% | 12,467 | +7,368 | +144.5% | 2024-12-31 |
Bank Of America Corp /De/ | $5.00 | 0.12% | 1,226 | +<1 | +0.08% | 2024-12-31 |
Blackrock, Inc. | $2.00 | 0.05% | 490 | 0 | 0% | 2024-12-31 |
Morgan Stanley | $0 | 0.01% | 100 | -60 | -37.5% | 2024-12-31 |
Jpmorgan Chase & Co | $0 | 0.01% | 100 | +100 | New | 2024-12-31 |
Sbi Securities Co., Ltd. | $0 | <0.01% | 18 | +18 | New | 2024-12-31 |
Group One Trading Llc | $0 | 0% | 3 | 0 | 0% | 2024-12-31 |